Neurocrine Clinical Site

San Diego, California 92123

6 studies enrolling now · 20 studies all time

What they study most

Anhedonia, Bipolar Disorder, Bipolar I Disorder, CAH - Congenital Adrenal Hyperplasia, Cerebral Palsy, Congenital Adrenal Hyperplasia, Dyskinesia, Major Depressive Disorder, Mania, Schizoaffective Disorder, Schizophrenia, Tardive Dyskinesia

Studies at this site

• An Assessment of Efficacy, Safety, and Pharmacokinetics of NBI-1117568 in Adults With Bipolar I Disorder With Current Mania — Recruiting now
• Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD) — Recruiting now
• A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor — Recruiting now
• NBI-1117568-SCZ3032: Long-Term Evaluation of NBI-1117568 in Adults With Schizophrenia — Recruiting now
• NBI-1117568-SCZ3029: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia — Recruiting now
• Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD) — Recruiting now
• Global Safety and Efficacy Registration Study of Crinecerfont for Congenital Adrenal Hyperplasia — Running, not enrolling
• Study to Assess the Efficacy, Safety, and Tolerability of Valbenazine for the Treatment of Dyskinesia Due to Cerebral Palsy — Completed
• Journey Study: Evaluate the Efficacy, Safety, and Tolerability of Valbenazine as Adjunctive Treatment for Schizophrenia — Completed
• Efficacy, Safety, Tolerability, and Pharmacokinetics of NBI-1117568 in Adults With Schizophrenia — Completed
• Study to Evaluate the Efficacy, Safety, and Tolerability of Luvadaxistat in Participants With Cognitive Impairment Associated With Schizophrenia — Stopped early
• Global Safety and Efficacy Registration Study of Crinecerfont in Pediatric Participants With Classic Congenital Adrenal Hyperplasia (CAHtalyst Pediatric Study) — Running, not enrolling
• Study to Assess the Efficacy and Safety of NBI-1065845 in Adults With Major Depressive Disorder (MDD) — Completed
• Study to Evaluate the Efficacy and Safety of Once-Weekly Oral NBI-1065846 in the Treatment of Anhedonia in MDD — Completed
• Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NBI-74788 (Crinecerfont) in Pediatric Participants With Congenital Adrenal Hyperplasia — Completed
• Safety and Efficacy of NBI-98854 in Pediatric Subjects With Tourette Syndrome — Stopped early
• Rollover Study for Continuing NBI-98854 Administration in Pediatric Subjects With Tourette Syndrome — Stopped early
• Open-Label Safety and Tolerability Study of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome — Completed
• Safety, Tolerability, and Efficacy of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome — Completed
• Persistence of Effect and Safety of Valbenazine for the Treatment of Tardive Dyskinesia — Completed